Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0073oc1.5 | Oral Communications 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Primary results from MATCH: A randomised controlled trial in primary aldosteronism

Wu Xilin , Senanayake Russell , Goodchild Emily , Bashari Waiel , Salsbury Jackie , Argentesi Giulia , O’Toole Samuel , Matson Matthew , Parvanta Laila , Marker Alison , Berney Daniel , Sahdev Anju , Bird Nicholas , McConnachie Alexander , McIntosh Alasdair , Laycock Kate , Cruickshank Kennedy , Cheow Heok , Gurnell Mark , Drake William , Brown Morris

Primary aldosteronism (PA) is considered the sole, often curable, cause of hypertension in 5–10% of patients. Yet there has been only one RCT, and practice has changed little since the advent of CT scanning. Adrenal vein sampling (AVS) and adrenalectomy remain the standard, invasive interventions, leading to a 50% reduction in pill count as the average clinical improvement.Study DesignIn MATCH (Is Metomidate PET-CT superior t...
shares

ea0086op2.1 | Adrenal and Cardiovascular | SFEBES2022

Novel radiolabeled ligand, Para-chloro-2-[18F]fluoroethyletomidate (CETO) compared to [11C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

Goodchild Emily , Senanayake Russell , Wu Xilin , Bashari Waiel , Salsbury Jackie , Argentesi Giulia , O'Toole Samuel , MacFarlane James , Laycock Kate , Gillett Dan , Boros Istvan , Aigbirhio Franklin , Sadhev Anju , Bird Nicholas , Hader Stefan , Warnes Victoria , Cruickshank Kennedy , Cheow Heok , Drake William , Gurnell Mark , Brown Morris

Introduction: Our MATCH study demonstrated 11-C ligand MTO was non-inferior to adrenal vein sampling in predicting surgical outcomes of adrenalectomy in patients with PA. The 20-min half-life of 11-C imposes logistic constraints. We investigated an 18-F ligand, CETO; its 2h half-life permits use in any facility with fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan capability.Objective: To compare the detection of aldosterone-producing ade...
shares

ea0086op2.3 | Adrenal and Cardiovascular | SFEBES2022

Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years

Goodchild Emily , Wu Xilin , Senanayake Russell , Bashari Waiel , Salsbury Jackie , Cabrera Claudia , Argentesi Giulia , O'Toole Samuel , MacFarlane James , Laycock Kate , Benu Daniela , Matson Matthew , Koo Brendan , Parvanta Laila , Hilliard Nick , Kosmoliaptsis Vasilis , Marker Alison , Berney Daniel , Tan Wilson , Foo Roger , Mein Charles , Wozniak Eva , Savage Emmanuel , Sahdev Anju , Bird Nicholas , Boros Istvan , Hader Stefan , Warnes Victoria , Gillett Dan , Dawnay Anne , Adeyeye Elizabeth , Prete Alessandro , Taylor Angela , Wiebke Arlt , Bhuva Anish , Aigbirhio Franklin , Manisty Charlotte , Cruickshank Kennedy , Cheow Heok , Gurnell Mark , Drake William , Brown Morris

Introduction: In a prospective within-patient study (MATCH) 11C-metomidate PET-CT (MTO) was an accurate non-invasive alternative to adrenal vein sampling in the detection of unilateral PA1. Post-adrenalectomy (ADX), 24/78 (30%) patients achieved complete clinical success (PASO consensus) at 6 months, but 75% achieved reduction in B-type natriuretic peptide (BNP).Aim: To determine: 1. the number of patients who sustain complete clinical success...
shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2023 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more